List of Canasa drug patents
Canasa is owned by Allergan.
Canasa contains Mesalamine.
Canasa has a total of 2 drug patents out of which 0 drug patents have expired.
Canasa was authorised for market use on 05 January, 2001.
Canasa is available in suppository;rectal dosage forms.
The generics of Canasa are possible to be released after 06 June, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8436051 | ALLERGAN | Mesalamine suppository |
Jun, 2028
(5 years from now) | |
| US8217083 | ALLERGAN | Mesalamine suppository |
Jun, 2028
(5 years from now) | |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 05 January, 2001
Treatment: NA
Dosage: SUPPOSITORY;RECTAL
How can I launch a generic of CANASA before it's patent expiration?
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic